Crescita Therapeutics Inc. (CRRTF)
- Previous Close
0.3200 - Open
0.3200 - Bid --
- Ask --
- Day's Range
0.3200 - 0.3200 - 52 Week Range
0.2500 - 0.5500 - Volume
1,000 - Avg. Volume
25 - Market Cap (intraday)
6.253M - Beta (5Y Monthly) 1.65
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0700 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. The company operates through three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. It owns proprietary platform technologies, including Multiplexed Molecular Penetration Enhancers and DuraPeel that supports the development of patented formulations that can deliver actives into or through the skin. The company's prescription products include Pliaglis, a topical local anesthetic cream that provides dermal analgesia on intact skin prior to superficial dermatological procedures; CTX-101, a Phase III topical formulation utilizing a corticosteroid in combination with MMPE technology to treat plaque psoriasis; CTX-102, a Phase I topical formulation utilizing MMPE technology to treat an undisclosed dermatological skin condition; and dermatology products in pre-clinical formulation utilizing MMPE technology for prescription treatments of skin diseases. Its non-prescription portfolio offers dermocosmetic products, such as face creams, cleansers, exfoliants, masks, serums, and suncare to treat mild acne, aging, dehydration, pigmentation, sensitivity, and rosacea under the Laboratoire Dr Renaud brand; and provides medical aesthetics under Pro-Derm and Alyria brands, for non-invasive and minimally invasive procedures or skincare treatments. In addition, it distributes NCTF Boost 135 HA, a skin revitalization solution; Obagi Medical products; and ART FILLER, hyaluronic acid-based dermal fillers. The company has a commercialization license agreement with Cantabria Labs Inc.; a development and commercialization license agreement with Taro Pharmaceuticals Inc.; and a distribution and promotion agreement with FILLMED. Crescita Therapeutics Inc. was founded in 2016 and is headquartered in Laval, Canada.
www.crescitatherapeutics.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: CRRTF
Performance Overview: CRRTF
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CRRTF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CRRTF
Valuation Measures
Market Cap
6.15M
Enterprise Value
198.94k
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.51
Price/Book (mrq)
0.45
Enterprise Value/Revenue
0.01
Enterprise Value/EBITDA
3.26
Financial Highlights
Profitability and Income Statement
Profit Margin
-11.33%
Return on Assets (ttm)
-4.61%
Return on Equity (ttm)
-9.95%
Revenue (ttm)
17.52M
Net Income Avi to Common (ttm)
-1.99M
Diluted EPS (ttm)
-0.0700
Balance Sheet and Cash Flow
Total Cash (mrq)
9.39M
Total Debt/Equity (mrq)
6.66%
Levered Free Cash Flow (ttm)
2.06M
Company Insights: CRRTF
CRRTF does not have Company Insights